Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology

M. Abdelrahim; A. Esmail; A. Mejia; M. Ouf; J.W. Franses; I. Bhan; C. Bridges; A. Tin; C. Brewer; V. Aushev; C. Palsuledesai; A. Jurdi; M. Liu; A. He

doi:10.1016/j.hpb.2025.07.051

Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology

M. Abdelrahim, A. Esmail, A. Mejia, M. Ouf, J.W. Franses, I. Bhan, C. Bridges, A. Tin, C. Brewer, V. Aushev, C. Palsuledesai, A. Jurdi, M. Liu, A. He

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). Here we evaluated the utility of circulating tumor DNA (ctDNA) to predict the risk of relapse/progression in patients with HCC.

Original language	English (US)
Pages (from-to)	S246
Journal	HPB
Volume	27
DOIs	https://doi.org/10.1016/j.hpb.2025.07.051
State	Published - 2025

Divisions

Medical Oncology

Access to Document

10.1016/j.hpb.2025.07.051

Cite this

Abdelrahim, M., Esmail, A., Mejia, A., Ouf, M., Franses, J. W., Bhan, I., Bridges, C., Tin, A., Brewer, C., Aushev, V., Palsuledesai, C., Jurdi, A., Liu, M., & He, A. (2025). Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology. HPB, 27, S246. https://doi.org/10.1016/j.hpb.2025.07.051

Abdelrahim, M , Esmail, A, Mejia, A, Ouf, M, Franses, JW, Bhan, I, Bridges, C, Tin, A, Brewer, C, Aushev, V, Palsuledesai, C, Jurdi, A, Liu, M & He, A 2025, 'Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology', HPB, vol. 27, pp. S246. https://doi.org/10.1016/j.hpb.2025.07.051

@article{4ad5feeadb3e47e7b1aea522fcfafe49,

title = "Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology",

abstract = "Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). Here we evaluated the utility of circulating tumor DNA (ctDNA) to predict the risk of relapse/progression in patients with HCC.",

author = "M. Abdelrahim and A. Esmail and A. Mejia and M. Ouf and J.W. Franses and I. Bhan and C. Bridges and A. Tin and C. Brewer and V. Aushev and C. Palsuledesai and A. Jurdi and M. Liu and A. He",

note = "doi: 10.1016/j.hpb.2025.07.051",

year = "2025",

doi = "10.1016/j.hpb.2025.07.051",

language = "English (US)",

volume = "27",

pages = "S246",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology

AU - Abdelrahim, M.

AU - Esmail, A.

AU - Mejia, A.

AU - Ouf, M.

AU - Franses, J.W.

AU - Bhan, I.

AU - Bridges, C.

AU - Tin, A.

AU - Brewer, C.

AU - Aushev, V.

AU - Palsuledesai, C.

AU - Jurdi, A.

AU - Liu, M.

AU - He, A.

N1 - doi: 10.1016/j.hpb.2025.07.051

PY - 2025

Y1 - 2025

N2 - Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). Here we evaluated the utility of circulating tumor DNA (ctDNA) to predict the risk of relapse/progression in patients with HCC.

AB - Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). Here we evaluated the utility of circulating tumor DNA (ctDNA) to predict the risk of relapse/progression in patients with HCC.

U2 - 10.1016/j.hpb.2025.07.051

DO - 10.1016/j.hpb.2025.07.051

M3 - Article

SN - 1365-182X

VL - 27

SP - S246

JO - HPB

JF - HPB

ER -

Personalized Tumor-informed ctDNA Assay for Early Recurrence Detection in Post-curative Hepatocellular Carcinoma: Insights from Transplant Oncology

Abstract

Divisions

Access to Document

Fingerprint

Cite this